Article Sidebar

pdf
Date Published: 25/09/2023
Abstract Views: 204
Views pdf: 94
DOI: https://doi.org/10.51298/vmj.v530i1B.6745
Issue
Vol. 530 No. 1B (2023)
Section
Các bài báo
How to Cite
Lê, H. T., Nguyễn Đại B., & Nguyễn, T. T. H. (2023). THE EFFICACY OF SECOND-LINE GEMCITABINE IN PATIENTS WITH PLATINUM-COMBINE FAILURE STAGE IV NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 530(1B). https://doi.org/10.51298/vmj.v530i1B.6745

THE EFFICACY OF SECOND-LINE GEMCITABINE IN PATIENTS WITH PLATINUM-COMBINE FAILURE STAGE IV NON-SMALL CELL LUNG CANCER

Hồng Thái Lê1,, Đại Bình Nguyễn1, Thị Thái Hòa Nguyễn2
1 HMU
2 K Hospital

Main Article Content

Abstract

Objectives: To evaluate the efficacy of second-line gemcitabine in patients with platinum-combine failure stage IV non- small cell lung cancer. Materials and methods: Descriptive, retrospective, longitudinal study follow-up of 60 patients with stage IV non-small cell lung cancer who received first-line chemotherapy with platinum-based chemotherapy with or without maintenance therapy. The disease progressed according to RECIST criteria and received second-line treatment with gemcitabine at National Cancer Hospital during the period from January 2020 to August 2023. Results: The mean age was 60,9 ± 8.5 (40-77); male/female ratio was 5,5/1; smoking ratio was 68,3%. The overall response rate (ORR) was 20%, the DCR was 58,3%. The mean progression-free survival (PFS) was 3,95 ± 3,51 months, the median progression-free survival was 2,75 months. Conclusion: Second-line gemcitabine is an option in patients with advanced stage lung cancer after failure of platinum-based chemotherapy regimen with good response rate and disease control rate.

Article Details

Keywords

non-small cell lung cancer, second-line gemcitabine, platinum-based chemotherapy.

References

Trần Văn Thuấn (2019), Hướng dẫn chẩn đoán và điều trị bệnh ung thư thường gặp, Nhà xuất bản Y học, Hà Nội.
2. Global Cancer Observatory. https://gco.iarc.fr/
3. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology. 2022;17(3):362-387. doi:10.1016/j.jtho.2021.11.003
4. Treatment of Stage IV Non-small Cell Lung Cancer - PMC. https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4694611/
5. Corrales L, Nogueira A, Passiglia F, et al. Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. Front Med (Lausanne). 2017;4:13. doi:10.3389/fmed.2017.00013
6. A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. PubMed. https://pubmed.ncbi.nlm.nih.gov
7. Phượng NT, Nghị ĐH. Kết quả hóa trị bước hai docetaxel bệnh ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV tại bệnh viện E. YHCĐ. 2023;64(1). doi:10.52163/yhc.v64i1.567
8. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial - The Lancethttps://www.thelancet.com/journals/ lancet/article /PIIS0140-6736(16)32517-X/fulltext
9. Trần Nguyên Bảo (2014). Đánh giá hiệu quả điều trị Docetaxel trong điều trị bước 2 UTPKTBN tại Bệnh viện Ung Bướu Hà Nội. Luận văn thạc sĩ Y học, Đại Học Y Hà Nội.
10. Second-Line Gemcitabine in Refractory Stage IV Non–Small-Cell Lung Cancer: A Phase II Trial - ScienceDirect. Accessed August 10, 2023. https://www.sciencedirect.com/ science/article/abs/pii/S1525730411706258